Scientific understanding and clinical management of Dupuytren disease

Nature Reviews Rheumatology

Volumn 6, Issue 12, 2010, Pages 715-726

  Shih, Barbara ^a   Bayat, Ardeshir ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADAM PROTEIN; CHONDROITIN SULFATE; CLOSTRIDIOPEPTIDASE A; COLLAGEN ANTIBODY; DERMATAN SULFATE; GELATINASE A; GLYCOSAMINOGLYCAN; GROWTH FACTOR; HLA DR ANTIGEN; LYSOPHOSPHATIDIC ACID; PLACEBO; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA2;

AGE DISTRIBUTION; ANTIGEN PRESENTATION; APONEUROSIS; CHROMOSOME ABERRATION; CLINICAL ASSESSMENT; CLINICAL TRIAL; DISEASE SEVERITY; DRUG EFFICACY; DUPUYTREN CONTRACTURE; EFFECTOR CELL; ENVIRONMENTAL FACTOR; ETHNICITY; FASCIOTOMY; FIBROMATOSIS; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOPATHOGENESIS; METATARSOPHALANGEAL JOINT; MOLECULAR DYNAMICS; MYOFIBROBLAST; NONHUMAN; PALMAR FASCIA; POSTOPERATIVE CARE; PRIORITY JOURNAL; PROXIMAL INTERPHALANGEAL JOINT; RANGE OF MOTION; RECURRENT DISEASE; REVIEW; RISK FACTOR; SEX DIFFERENCE; SKIN NODULE; SPLINTING; SURGICAL TECHNIQUE;

ALCOHOL DRINKING; DUPUYTREN CONTRACTURE; FASCIA; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MICROBIAL COLLAGENASE; RISK FACTORS; SMOKING;

EID: 78649818084     PISSN: 17594790     EISSN: 17594804     Source Type: Journal    
DOI: 10.1038/nrrheum.2010.180     Document Type: Review

References (126)

1. Bayat, A. & McGrouther, D. A. Management of Dupuytren's disease- clear advice for an elusive condition. Ann. R. Coll. Surg. Engl. 88, 3-8 (2006).
2. Stahl, S. & Calif, E. Dupuytren's palmar contracture in women. Isr. Med. AssoC. J. 10, 445-447 (2008).
3. Anthony, S. G., Lozano-Calderon, S. A., Simmons, B. P. & Jupiter, J. B. Gender ratio of Dupuytren's disease in the modern U. S. population. Hand (NY) 3, 87-90 (2008).
4. Hindocha, S., McGrouther, D. A. & Bayat, A. Epidemiological evaluation of Dupuytren's disease incidence and prevalence rates in relation to etiology. Hand (NY) 4, 256-269 (2009).
5. Bayat, A., Cunliffe, E. J. & McGrouther, D. A. Assessment of clinical severity in Dupuytren's disease. Br. J. Hosp. Med. (Lond.) 68, 604-609 (2007).
6. Bayat, A. & McGrouther, D. A. Dupuytren's disease. Surgery 24, 373-375 (2006).
7. Hindocha, S., John, S., Stanley, J. K., watson, S. J. & Bayat, A. The heritability of Dupuytren's disease: familial aggregation and its clinical significance. J. Hand Surg. Am. 31, 204-210 (2006).
8. Hindocha, S., Stanley, J. K., watson, S. & Bayat, A. Dupuytren's diathesis revisited: Evaluation of prognostic indicators for risk of disease recurrence. J. Hand Surg. Am. 31, 1626-1634 (2006).
9. Luck, J. V. Dupuytren's contracture; a new concept of the pathogenesis correlated with surgical management. J. Bone Joint Surg. Am. 41-a, 635-664 (1959).
10. Wurster-Hill, D. H., Brown, F., Park, J. P. & Gibson, S. H. Cytogenetic studies in Dupuytren contracture. Am. J. Hum. Genet. 43, 285-292 (1988).
11. Howard, J. C. et al. wound healing-associated proteins Hsp47 and fibronectin are elevated in Dupuytren's contracture. J. Surg. Res. 117, 232-238 (2004).
12. Brickley-Parsons, D., Glimcher, M. J., Smith, R. J., Albin, R. & Adams, J. P. Biochemical changes in the collagen of the palmar fascia in patients with Dupuytren's disease. J. Bone Joint Surg. Am. 63, 787-797 (1981).
13. Tomasek, J. J., Gabbiani, G., Hinz, B., Chaponnier, C. & Brown, R. A. Myofibroblasts and mechano-regulation of connective tissue remodelling. Nat. ReV. Mol. Cell Biol. 3, 349-363 (2002).
14. Lam, w. L., Rawlins, J. M., Karoo, R. O., Naylor, I. & Sharpe, D. T. Re-visiting Luck's classification: a histological analysis of Dupuytren's disease. J. Hand Surg. Eur. Vol. 35, 312-317 (2010).
15. Burge, P. Genetics of Dupuytren's disease. Hand Clin. 15, 63-71 (1999).
16. Hart, M. G. & Hooper, G. Clinical associations of Dupuytren's disease. Postgrad. Med. J. 81, 425-428 (2005).
17. Ling, R. S. The genetic factor in Dupuytren's disease. J. Bone Joint Surg. Br. 45, 709-718 (1963).
18. Bayat, A. et al. Genetic susceptibility in Dupuytren's disease. TGF-β1 polymorphisms and Dupuytren's disease. J. Bone Joint Surg. Br. 84, 211-215 (2002).
19. Hu, F. Z. et al. Mapping of an autosomal dominant gene for Dupuytren's contracture to chromosome 16q in a Swedish family. Clin. Genet. 68, 424-429 (2005).
20. Shih, B., Brown, J. J., Armstrong, D. J., Lindau, T. & Bayat, A. Differential gene expression analysis of subcutaneous fat, fascia, and skin overlying a Dupuytren's disease nodule in comparison to control tissue. Hand (NY) 4, 294-301 (2009).
21. Badalamente, M. A., Sampson, S. P., Hurst, L. C., Dowd, A. & Miyasaka, K. The role of transforming growth factor β in Dupuytren's disease. J. Hand Surg. Am. 21, 210-215 (1996).
22. Berndt, A. et al. TGF β and bFGF synthesis and localization in Dupuytren's disease (nodular palmar fibromatosis) relative to cellular activity, myofibroblast phenotype and oncofetal variants of fibronectin. Histochem. J. 27, 1014-1020 (1995).
23. Tse, R., Howard, J., WU, Y. & Gan, B. S. Enhanced Dupuytren's disease fibroblast populated collagen lattice contraction is independent of endogenous active TGF-β2. BMC Musculoskelet. Disord. 5, 41 (2004).
24. Zhang, A. Y. et al. Gene expression analysis of Dupuytren's disease: the role of TGF-β2. J. Hand Surg. Eur. Vol. 33, 783-790 (2008).
25. Bayat, A. et al. Genetic susceptibility in Dupuytren's disease: lack of association of a novel transforming growth factor β2 polymorphism in Dupuytren's disease. J. Hand Surg. Br. 27, 47-49 (2002).
26. Bayat, A., Stanley, J. K., watson, J. S., Ferguson, M. w. & Ollier, w. E. Genetic susceptibility to Dupuytren's disease: transforming growth factor β receptor (TGFβR) gene polymorphisms and Dupuytren's disease. Br. J. Plast. Surg. 56, 328-333 (2003). (Pubitemid 36927264)
27. Kojima, S. et al. Transcriptional activation of urokinase by the Kruppel-like factor Zf9/COPEB activates latent TGF-β1 in vascular endothelial cells. Blood 95, 1309-1316 (2000).
28. Amuthan, G. et al. Mitochondria-to-nucleus stress signaling induces phenotypic changes, tumor progression and cell invasion. EMBO J. 20, 1910-1920 (2001).
29. Bayat, A., watson, J. S., Stanley, J. K., Ferguson, M. W. & Ollier, w. E. Genetic susceptibility to Dupuytren disease: association of Zf9 transcription factor gene. Plast. Reconstr. Surg. 111, 2133-2139 (2003).
30. Bayat, A. et al. Identification of a novel mitochondrial mutation in Dupuytren's disease using multiplex DHPLC. Plast. Reconstr. Surg. 115, 134-141 (2005).
31. Bonnici, A. V., Birjandi, F., Spencer, J. D., Fox, S. P. & Berry, A. C. Chromosomal abnormalities in Dupuytren's contracture and carpal tunnel syndrome. J. Hand Surg. Br. 17, 349-355 (1992).
32. Dal Cin, P., De Smet, L., Sciot, R., van Damme, B. & Van Den Berghe, H. Trisomy 7 and trisomy 8 in dividing and non-dividing tumor cells in Dupuytren's disease. Cancer Genet. Cytogenet. 108, 137-140 (1999).
33. Casalone, R. et al. Cytogenetic and interphase cytogenetic analyses reveal chromosome instability but no clonal trisomy 8 in Dupuytren contracture. Cancer Genet. Cytogenet. 99, 73-76 (1997).
34. Kaur, S., Forsman, M., Ryhanen, J., Knuutila, S. & Larramendy, M. L. No gene copy number changes in Dupuytren's contracture by array comparative genomic hybridization. Cancer Genet. Cytogenet. 183, 6-8 (2008).
35. Shih, B. B., Tassabehji, M., watson, J. S., McGrouther, A. D. & Bayat, A. Genome-wide high- resolution screening in Dupuytren's disease reveals common regions of DNA copy number alterations. J. Hand Surg. Am. 35, 1172-1183 (2010).
36. Neumüller, J., Menzel, J. & Millesi, H. Prevalence of HLA-DR3 and autoantibodies to connective tissue components in Dupuytren's contracture. Clin. Immunol. Immunopathol. 71, 142-148 (1994).
37. Pereira, R. S., Black, C. M., Turner, S. M. & Spencer, J. D. Antibodies to collagen types I-vI in Dupuytren's contracture. J. Hand Surg. Br. 11, 58-60 (1986).
38. Hunter, T., Shanahan, w. R. Jr, Robertson, G. A., Stranc, M. F. & Schroeder, M. L. The distribution of histocompatibility antigens in patients with Dupuytren's contracture. Arthritis Rheum. 24, 1218-1219 (1981).
39. Tait, B. D. & Mackay, I. R. HLA phenotypes in Dupuytren's contracture. Tissue Antigens 19, 240-241 (1982).
40. Williams, P. L., Dann, J., James, D. C. & Timlin, D. Histocompatibility antigens in subgroups of Dupuytren's contracture. Br. J. Rheumatol. 22, 60-61 (1983).
41. Spencer, J. D. & walsh, K. I. Histocompatibility antigen patterns in Dupuytren's contracture. J. Hand Surg. Br. 9, 276-278 (1984).
42. Brown, J. J., Ollier, w., Thomson, w. & Bayat, A. Positive association of HLA-DRB1*15 with Dupuytren's disease in Caucasians. Tissue Antigens 72, 166-170 (2008).
43. Andrew, J. G., Andrew, S. M., Ash, A. & Turner, B. An investigation into the role of inflammatory cells in Dupuytren's disease. J. Hand Surg. Br. 16, 267-271 (1991).
44. Sugden, P., Andrew, J. G., Andrew, S. M. & Freemont, A. J. Dermal dendrocytes in Dupuytren's disease: a link between the skin and pathogenesis? J. Hand Surg. Br. 18, 662-666 (1993).
45. Baird, K. S., Alwan, w. H., Crossan, J. F. & wojciak, B. T-cell-mediated response in Dupuytren's disease. Lancet 341, 1622-1623 (1993).
46. Gudmundsson, K. G., Arngrimsson, R., Arinbjarnarson, S., Olafsson, A. & Jonsson, T. T- and B-lymphocyte subsets in patients with Dupuytren's disease. Correlations with disease severity. J. Hand Surg. Br. 23, 724-727 (1998).
47. Qureshi, F. I., Hornigold, R., Spencer, J. D. & Hall, S. M. Langerhans cells in Dupuytren's contracture. J. Hand Surg. Br. 26, 362-367 (2001).
48. Baird, K. S., Crossan, J. F. & Ralston, S. H. Abnormal growth factor and cytokine expression in Dupuytren's contracture. J. Clin. Pathol. 46, 425-428 (1993).
49. Augoff, K., Kula, J., Gosk, J. & Rutowski, R. Epidermal growth factor in Dupuytren's disease. Plast. Reconstr. Surg. 115, 128-133 (2005).
50. Augoff, K., Tabola, R., Kula, J., Gosk, J. & Rutowski, R. Epidermal growth factor receptor (EGF-R) in Dupuytren's disease. J. Hand Surg. Br. 30, 570-573 (2005).
51. Gonzalez, A. M. et al. Basic fibroblast growth factor in Dupuytren's contracture. Am. J. Pathol. 141, 661-671 (1992).
52. Badalamente, M. A., Hurst, L. C., Grandia, S. K. & Sampson, S. P. Platelet-derived growth factor in Dupuytren's disease. J. Hand Surg. Am. 17, 317-323 (1992).
53. Terek, R. M., Jiranek, w. A., Goldberg, M. J., wolfe, H. J. & Alman, B. A. The expression of platelet-derived growth-factor gene in Dupuytren contracture. J. Bone Joint Surg. Am. 77, 1-9 (1995).
54. Vi, L., Njarlangattil, A., wu, Y., Gan, B. S. & O'Gorman, D. B. Type-1 collagen differentially alters β-catenin accumulation in primary Dupuytren's disease cord and adjacent palmar fascia cells. BMC Musculoskelet. Disord. 10, 72 (2009).
55. Lee, L. C. et al. Expression of a novel gene, MafB, in Dupuytren's disease. J. Hand Surg. Am. 31, 211-218 (2006).
56. Rehman, S. et al. Molecular phenotypic descriptors of Dupuytren's disease defined using informatics analysis of the transcriptome. J. Hand Surg. Am. 33, 359-372 (2008).
57. Bazin, S. et al. Biochemistry and histology of the connective tissue of Dupuytren's disease lesions. Eur. J. Clin. Invest. 10, 9-16 (1980).
58. Magro, G., Lanzafame, S. & Micali, G. Co- ordinate expression of α5β1 integrin and fibronectin in Dupuytren's disease. Acta Histochem. 97, 229-233 (1995).
59. Magro, G., Fraggetta, F., Travali, S. & Lanzafame, S. Immunohistochemical expression and distribution of α2β1, α6β1, α5β1 integrins and their extracellular ligands, type Iv collagen, laminin and fibronectin in palmar fibromatosis. Gen. Diagn. Pathol. 143, 203-208 (1997).
60. Qian, A., Meals, R. A., Rajfer, J. & Gonzalez- Cadavid, N. F. Comparison of gene expression profiles between Peyronie's disease and Dupuytren's contracture. Urology 64, 399-404 (2004).
61. Shih, B. et al. Identification of biomarkers in Dupuytren's disease by comparative analysis of fibroblasts versus tissue biopsies in disease- specific phenotypes. J. Hand Surg. Am. 34, 124-136 (2009).
62. Vi, L. et al. Periostin differentially induces proliferation, contraction and apoptosis of primary Dupuytren's disease and adjacent palmar fascia cells. Exp. Cell Res. 315, 3574-3586 (2009).
63. Varallo, V. M. et al. β-catenin expression in Dupuytren's disease: potential role for cell- matrix interactions in modulating β-catenin levels in vivo and in vitro. Oncogene 22, 3680-3684 (2003).
64. Mosakhani, N. et al. Unique microRNA profile in Dupuytren's contracture supports deregulation of β-catenin pathway. Mod. Pathol. doi:10.1038/ modpathol.2010.146.
65. Flint, M. H., Gillard, G. C. & Reilly, H. C. The glycosaminoglycans of Dupuytren's disease. Connect. Tissue Res. 9, 173-179 (1982).
66. Tunn, S., Gurr, E., Delbruck, A., Buhr, T. & Flory, J. The distribution of unsulphated and sulphated glycosaminoglycans in palmar fascia from patients with Dupuytren's disease and healthy subjects. J. Clin. Chem. Clin. Biochem. 26, 7-14 (1988).
67. Kozma, E. M., Olczyk, K., wisowski, G., Glowacki, A. & Bobinski, R. Alterations in the extracellular matrix proteoglycan profile in Dupuytren's contracture affect the palmar fascia. J. Biochem. 137, 463-476 (2005).
68. Montgomery, E., Lee, J. H., Abraham, S. C. & wu, T. T. Superficial fibromatoses are genetically distinct from deep fibromatoses. Mod. Pathol. 14, 695-701 (2001).
69. Degreef, I., De Smet, L., Sciot, R., Cassiman, J. J. & Tejpar, S. β-catenin overexpression in Dupuytren's disease is unrelated to disease recurrence. Clin. Orthop. Relat. Res. 467, 838-845 (2009).
70. O'Gorman, D. B., wu, Y., Seney, S., Zhu, R. D. & Gan, B. S. wnt expression is not correlated with β-catenin dysregulation in Dupuytren's disease. J. Negat. Results Biomed. 5, 13 (2006).
71. Parry, D. A., Flint, M. H., Gillard, G. C. & Craig, A. S. A role for glycosaminoglycans in the development of collagen fibrils. FEBS Lett. 149, 1-7 (1982).
72. Throckmorton, D. C., Brogden, A. P., Min, B., Rasmussen, H. & Kashgarian, M. PDGF and TGF-β mediate collagen production by mesangial cells exposed to advanced glycosylation end products. Kidney Int. 48, 111-117 (1995).
73. Ulrich, D., Hrynyschyn, K. & Pallua, N. Matrix metalloproteinases and tissue inhibitors of metalloproteinases in sera and tissue of patients with Dupuytren's disease. Plast. Reconstr. Surg. 112, 1279-1286 (2003).
74. Ulrich, D., Ulrich, F., Piatkowski, A. & Pallua, N. Expression of matrix metalloproteinases and their inhibitors in cords and nodules of patients with Dupuytren's disease. Arch. Orthop. Trauma Surg. 129, 1453-1459 (2009).
75. Tarlton, J. F. et al. Mechanical stress in vitro induces increased expression of MMPs 2 and 9 in excised Dupuytren's disease tissue. J. Hand Surg. Br. 23, 297-302 (1998).
76. Augoff, K., Ratajczak, K., Gosk, J., Tabola, R. & Rutowski, R. Gelatinase A activity in Dupuytren's disease. J. Hand Surg. Am. 31, 1635-1639 (2006).
77. Johnston, P., Larson, D., Clark, I. M. & Chojnowski, A. J. Metalloproteinase gene expression correlates with clinical outcome in Dupuytren's disease. J. Hand Surg. Am. 33, 1160-1167 (2008).
78. Townley, W. A., Cambrey, A. D., Khaw, P. T. & Grobbelaar, A. O. Matrix metalloproteinase inhibition reduces contraction by Dupuytren fibroblasts. J. Hand Surg. Am. 33, 1608-1616 (2008).
79. Shin, S. S., Liu, C., Chang, E. Y., Carlson, C. S. & Di Cesare, P. E. Expression of bone morphogenetic proteins by Dupuytren's fibroblasts. J. Hand Surg. Am. 29, 809-814 (2004).
80. Forsman, M. et al. The expression of myoglobin and ROR2 protein in Dupuytren's disease. J. Surg. Res. 15, 271-275 (2008).
81. Pagnotta, A., Specchia, N. & Greco, F. Androgen receptors in Dupuytren's contracture. J. Orthop. Res. 20, 163-168 (2002).
82. Lyall, H. A. Dupuytren's disease in identical twins. J. Hand Surg. Br. 18, 368-370 (1993).
83. Godtfredsen, N. S., Lucht, H., Prescott, E., Sorensen, T. I. & Gronbaek, M. A prospective study linked both alcohol and tobacco to Dupuytren's disease. J. Clin. Epidemiol. 57, 858-863 (2004).
84. Burke, F. D., Proud, G., Lawson, I. J., McGeoch, K. L. & Miles, J. N. An assessment of the effects of exposure to vibration, smoking, alcohol and diabetes on the prevalence of Dupuytren's disease in 97,537 miners. J. Hand Surg. Eur. Vol. 32, 400-406 (2007).
85. Burge, P., Hoy, G., Regan, P. & Milne, R. Smoking, alcohol and the risk of Dupuytren's contracture. J. Bone Joint Surg. Br. 79, 206-210 (1997).
86. Liss, G. M. & Stock, S. R. Can Dupuytren's contracture be work-related?: review of the evidence. Am. J. Ind. Med. 29, 521-532 (1996).
87. Gudmundsson, K. G., Arngrimsson, R., Sigfusson, N., Bjornsson, A. & Jonsson, T. Epidemiology of Dupuytren's disease: clinical, serological, and social assessment. The Reykjavik Study. J. Clin. Epidemiol. 53, 291-296 (2000).
88. Noble, J., Heathcote, J. G. & Cohen, H. Diabetes mellitus in the aetiology of Dupuytren's disease. J. Bone Joint Surg. Br. 66, 322-325 (1984).
89. Critchley, E. M., Vakil, S. D., Hayward, H. W. & Owen, V. M. Dupuytren's disease in epilepsy: result of prolonged administration of anticonvulsants. J. Neurol. Neurosurg. Psychiatry 39, 498-503 (1976).
90. Gupta, R. et al. The effect of shear stress on fibroblasts derived from Dupuytren's tissue and normal palmar fascia. J. Hand Surg. Am. 23, 945-950 (1998).
91. Bergenudd, H., Lindgarde, F. & Nilsson, B. E. Prevalence of Dupuytren's contracture and its correlation with degenerative changes of the hands and feet and with criteria of general health. J. Hand Surg. Br. 18, 254-257 (1993).
92. Arafa, M., Noble, J., Royle, S. G., Trail, I. A. & Allen, J. Dupuytren's and epilepsy revisited. J. Hand Surg. Br. 17, 221-224 (1992).
93. Bower, M., Nelson, M. & Gazzard, B. G. Dupuytren's contractures in patients infected with HIV. BMJ 300, 164-165 (1990).
94. Smith, S. P., Devaraj, V. S. & Bunker, T. D. The association between frozen shoulder and Dupuytren's disease. J. Shoulder Elbow Surg. 10, 149-151 (2001).
95. Wilbrand, S., Ekbom, A. & Gerdin, B. Cancer incidence in patients treated surgically for Dupuytren's contracture. J. Hand Surg. Br. 25, 283-287 (2000).
96. Wilbrand, S., Ekbom, A. & Gerdin, B. Dupuytren's contracture and sarcoma. J. Hand Surg. Br. 27, 50-52 (2002).
97. French, P. D., Kitchen, V. S. & Harris, J. R. Prevalence of Dupuytren's contracture in patients infected with HIV. BMJ 301, 967 (1990).
98. Arafa, M., Steingold, R. F. & Noble, J. The incidence of Dupuytren's disease in patients with rheumatoid arthritis. J. Hand Surg. Br. 9, 165-166 (1984).
99. Hueston, J. The role of the skin in Dupuytren's disease. Ann. R. Coll. Surg. Engl. 67, 372-375 (1985).
100. Hoopes, J. E., Jabaley, M. E., Su, C. T., Wilgis, S. & Im, M. J. Enzymes of glucose metabolism in palmar fascia and Dupuytren's contracture. J. Hand Surg. Am. 2, 62-65 (1977).
101. Tonkin, M. A., Burke, F. D. & varian, J. P. Dupuytren's contracture: a comparative study of fasciectomy and dermofasciectomy in one hundred patients. J. Hand Surg. Br. 9, 156-162 (1984).
102. Flint, M. H. in The Genesis of the Palmar Lesion. (eds McFarlane, R. M., McGrouther, D. A. & Flint, M. H.) 140-145 (Churchill Livingstone, New York, 1990).
103. Rabinowitz, J. L., Ostermann, L. Jr, Bora, F. w. & Staeffen, J. Lipid composition and de novo lipid biosynthesis of human palmar fat in Dupuytren's disease. Lipids 18, 371-374 (1983).
104. Gabbiani, G. & Majno, G. Dupuytren's contracture: fibroblast contraction? An ultrastructural study. Am. J. Pathol. 66, 131-146 (1972).
105. Tomasek, J. J., Schultz, R. J. & Haaksma, C. J. Extracellular matrix-cytoskeletal connections at the surface of the specialized contractile fibroblast (myofibroblast) in Dupuytren disease. J. Bone Joint Surg. Am. 69, 1400-1407 (1987).
106. Rayan, G. M., Parizi, M. & Tomasek, J. J. Pharmacologic regulation of Dupuytren's fibroblast contraction in vitro. J. Hand Surg. Am. 21, 1065-1070 (1996).
107. Parizi, M., Howard, E. w. & Tomasek, J. J. Regulation of LPA-promoted myofibroblast contraction: role of Rho, myosin light chain kinase, and myosin light chain phosphatase. Exp. Cell Res. 254, 210-220 (2000).
108. Badalamente, M. A., Hurst, L. C. & Sampson, S. P. Prostaglandins influence myofibroblast contractility in Dupuytren's disease. J. Hand Surg. Am. 13, 867-871 (1988).
109. Murrell, G. A., Francis, M. J. & Bromley, L. Free radicals and Dupuytren's contracture. Br. Med. J. (Clin. Res. Ed.) 295, 1373-1375 (1987).
110. Murrell, G. A., Francis, M. J. & Bromley, L. Modulation of fibroblast proliferation by oxygen free radicals. Biochem. J. 265, 659-665 (1990).
111. Murrell, G. A. An insight into Dupuytren's contracture. Ann. R. Coll. Surg. Engl. 74, 156-160 (1992).
112. Hindocha, S., Stanley, J. K., watson, J. S. & Bayat, A. Revised Tubiana's staging system for assessment of disease severity in Dupuytren's disease-preliminary clinical findings. Hand (NY) 3, 80-86 (2008).
113. Au-Yong, I. T., wildin, C. J., Dias, J. J. & Page, R. E. A review of common practice in Dupuytren surgery. Tech. Hand Up Extrem. Surg. 9, 178-187 (2005).
114. Shaw, R. B. Jr, Chong, A. K., Zhang, A., Hentz, V. R. & Chang, J. Dupuytren's disease: history, diagnosis, and treatment. Plast. Reconstr. Surg. 120, 44e-54e (2007).
115. Hurst, L. C. et al. Injectable collagenase Clostridium histolyticum for Dupuytren's contracture. N. Engl. J. Med. 361, 968-979 (2009).
116. Badalamente, M. A., Hurst, L. C. & Hentz, V. R. Collagen as a clinical target: nonoperative treatment of Dupuytren's disease. J. Hand Surg. Am. 27, 788-798 (2002).
117. Seegenschmiedt, M. H., Olschewski, T. & Guntrum, F. Radiotherapy optimization in early- stage Dupuytren's contracture: first results of a randomized clinical study. Int. J. Radiat. Oncol. Biol. Phys. 49, 785-798 (2001).
118. Betz, N. et al. Radiotherapy in early-stage Dupuytren's contracture. Long-term results after 13 years. Strahlenther Onkol. 186, 82-90 (2010).
119. Pittet, B. et al. Effect of γ-interferon on the clinical and biologic evolution of hypertrophic scars and Dupuytren's disease: an open pilot study. Plast. Reconstr. Surg. 93, 1224-1235 (1994).
120. Meek, R. M., McLellan, S., Reilly, J. & Crossan, J. F. The effect of steroids on Dupuytren's disease: role of programmed cell death. J. Hand Surg. Br. 27, 270-273 (2002).
121. Rives, K., Gelberman, R., Smith, B. & Carney, K. Severe contractures of the proximal interphalangeal joint in Dupuytren's disease: results of a prospective trial of operative correction and dynamic extension splinting. J. Hand Surg. Am. 17, 1153-1159 (1992).
122. Ebskov, L. B., Boeckstyns, M. E., Sorensen, A. I. & Soe-Nielsen, N. Results after surgery for severe Dupuytren's contracture: does a dynamic extension splint influence outcome? Scand. J. Plast. Reconstr Surg. Hand Surg. 34, 155-160 (2000).
123. Larson, D. & Jerosch-Herold, C. Clinical effectiveness of post-operative splinting after surgical release of Dupuytren's contracture: a systematic review. BMC Musculoskelet. Disord. 9, 104 (2008).
124. Brenner, P. & Rayan, G. M. Dupuytren's Disease: a Concept of Surgical Treatment (New York, Springer, 2003).
125. Watt, A. J., Curtin, C. M. & Hentz, V. R. Collagenase injection as nonsurgical treatment of dupuytren's disease: 8-year follow-up. J. Hand Surg. Am. 35, 534.e1-539.e1 (2010).
126. Johnston, P. et al. A complete expression profile of matrix-degrading metalloproteinases in Dupuytren's disease. J. Hand Surg. Am. 32, 343-351 (2007).